// App-Quantinova.ai

1715 : Pharmacokinetics/Pharmacodynamics, Safety and Efficacy of Crizanlizumab in Patients with Sickle Cell Disease and a History of Vaso-Occlusive Crises: Results from the Phase II, Multicenter, Open-Label Solace-Adults Study

Researchers

Presenter

  • Darla Liles

Principal Investigators

  • Kim Smith-Whitley

  • R Clark Brown

  • Nirmish Shah

  • Santosh M Nair

  • Chiaki Tanaka

  • Shankaranand Bodla

  • Gessami Sanchez-Olle

  • Urs Albers

  • Julie Kanter

Medical Centers

  • Department of Hematology/Oncology, East Carolina University, Greenville, NC

  • Division of Human Genetics, Children's Hospital of Philadelphia, Philadelphia, PA

  • Emory University, Aflac Cancer and Blood Disorders Center, Childrens Healthcare of Atlanta, Atlanta, GA

  • Duke University Medical Center, Durham, NC

  • Mid-Florida Hematology and Oncology Associates, Orange City, FL

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • GCE Solutions, Manchester, United Kingdom

  • Novartis AG, Basel, Switzerland

  • Div of Hematology and Oncology, Univ of Alabama, Birmingham, AL

Locations

  • United States

  • United Kingdom

  • Switzerland

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Sickle cell anemia

Biomarkers

  • Stearoyl-CoA desaturase

  • Volatile organic compounds

Drug/Treatment

  • SelG1

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

  • Open Label

  • Multicenteric

Phase

  • II

Study Id's

  • NCT03264989

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved